

QCL PHARMA LIMITED
Abridged Unaudited Financial Statements
for the financial period from 04 September 2024 to 31 August 2025

QCL PHARMA LIMITED

Abridged Unaudited Financial Statements

for the financial period from 04 September 2024 to 31 August 2025

Contents

Company Information	2
Balance Sheet	3
Notes to the Financial Statements	4

QCL PHARMA LIMITED

COMPANY INFORMATION

for the financial period from 04 September 2024 to 31 August 2025

DIRECTOR Eimear Mullooly (Appointed 04 September 2024)

SECRETARY Roolt Business Services Limited

REGISTERED OFFICE Church Street
Strokestown
Roscommon
F42 W208
Ireland
Ireland

COMPANY NUMBER 771074

CHARTERED ACCOUNTANTS Lizdan Business Services Limited t/a Kinore
Ground Floor
71 Baggot Street Lower
Dublin
D02 P593
Ireland

BANKERS Bank of Ireland
The Square
Roscommon
F42 X803
Ireland

QCL PHARMA LIMITED

BALANCE SHEET

As at 31 August 2025

	31.08.2025
	€
Current assets	38,141
Prepayments and accrued income	14,000
Creditors: amounts falling due within one year	(14,590)
Net current assets	37,551
Total assets less current liabilities	37,551
Accruals and deferred income	(1,182)
Net assets	36,369
Capital and reserves	36,369

I, as director of QCL Pharma Limited, state that:

- The Company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
- The Company is availing itself of the exemption on the grounds that the conditions specified in s.358 are satisfied,
- The shareholders of the Company have not served a notice on the Company under s.334(1) in accordance with s.334(2),
- I acknowledge the Company's obligations under the Companies Act 2014 and to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the Company at the end of its financial period and of its profit or loss for such a period and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the Company,
- The Company has relied on the specified exemption contained in s.352 Companies Act 2014 and has done so on the grounds that the Company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with s.353 Companies Act 2014.

These financial statements have been prepared in accordance with the micro companies regime.

The financial statements of QCL Pharma Limited (registered number: 771074) were approved and authorised for issue by the director on 10 February 2026 and were signed on its behalf by:

Eimear Mullooly

Eimear Mullooly
Director

QCL PHARMA LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial period from 04 September 2024 to 31 August 2025

1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial period, unless otherwise stated.

General information and basis of accounting

QCL Pharma Limited (registered number 771074) (the Company) is a private company, limited by shares, registered in Ireland under the Companies Act 2014. The address of the registered office is Church Street, Strokestown, Roscommon, F42 W208, Ireland, Ireland.

The financial statements have been prepared under the historical cost convention and in accordance with FRS 105 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

The functional currency of QCL Pharma Limited is considered to be EUR because that is the currency of the primary economic environment in which the Company operates.

These financial statements are separate financial statements.

Going concern

The director has assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The director has a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Balance Sheet date are reported at the rates of exchange prevailing at that date.

Exchange differences are recognised in the Profit and Loss Account in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

Turnover

Turnover is recognised at the transaction value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The transaction value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

QCL PHARMA LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS (continued) for the financial period from 04 September 2024 to 31 August 2025

Taxation

Current tax

Current tax, including Irish corporation tax and foreign tax, is provided at amounts expected to be paid (or recovered) using the tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

A provision is recognised for those matters for which the tax determination is uncertain but it is considered probable that there will be a future outflow of funds to a tax authority. The provisions are measured at the best estimate of the amount expected to become payable. The assessment is based on the judgement of tax professionals within the Company supported by previous experience in respect of such activities and in certain cases based on specialist independent tax advice.

Where items recognised in other comprehensive income or equity are chargeable to or deductible for tax purposes, the resulting current or deferred tax expense or income is recognised in the same component of comprehensive income or equity as the transaction or other event that resulted in the tax expense or income.

Current tax assets and liabilities are offset only when there is a legally enforceable right to set off the amounts and the Company intends either to settle on a net basis or to realise the asset and settle the liability simultaneously.

Trade and other debtors

Trade and other debtors are initially recognised at transaction value and thereafter the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Trade and other creditors

Trade and other creditors are initially recognised at transaction value.

Ordinary share capital

The ordinary share capital of the Company is presented as equity.

Post Balance Sheet events

There have been no significant events affecting the company since the year end.

QCL PHARMA LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS (continued)
for the financial period from 04 September 2024 to 31 August 2025

2. Appropriation of profit and loss

	Profit and loss account
	€
At 04 September 2024	-
Profit for the financial period	36,269
Total comprehensive income	<u>36,269</u>
At 31 August 2025	<u><u>36,269</u></u>